Cell‐free production of a therapeutic protein: Expression, purification, and characterization of recombinant streptokinase using a CHO lysate
Autor: | Yordan Kostov, Michael Tolosa, Chandrasekhar Gurramkonda, Tzu-Chiang Han, Joseph E. Taris, David W. Wood, Merideth A. Cooper, Douglas D. Frey, Christina Dinkins, Niloufar Pezeshk, Leah Tolosa, Adil Zuber, Chariz Peñalber-Johnstone, Manohar Pilli, Nicholas Selock, Govind Rao, Kevin Tran |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Glycosylation Lysis medicine.drug_class Green Fluorescent Proteins Bioengineering CHO Cells Protein tag Complex Mixtures Biology Monoclonal antibody Applied Microbiology and Biotechnology Green fluorescent protein law.invention 03 medical and health sciences chemistry.chemical_compound Cricetulus law Protein biosynthesis medicine Animals Streptokinase Cell-Free System Recombinant Proteins 030104 developmental biology chemistry Biochemistry Recombinant DNA Intein Biotechnology |
Zdroj: | Biotechnology and Bioengineering. 115:92-102 |
ISSN: | 1097-0290 0006-3592 |
DOI: | 10.1002/bit.26439 |
Popis: | The use of cell-free systems to produce recombinant proteins has grown rapidly over the past decade. In particular, cell-free protein synthesis (CFPS) systems based on mammalian cells provide alternative methods for the production of many proteins, including those that contain disulfide bonds, glycosylation, and complex structures such as monoclonal antibodies. In the present study, we show robust production of turbo green fluorescent protein (tGFP) and streptokinase in a cell-free system using instrumented mini-bioreactors for highly reproducible protein production. We achieved recombinant protein production (∼600 μg/ml of tGFP and 500 μg/ml streptokinase) in 2.5 hr of expression time, comparable to previously reported yields for cell-free protein expression. Also, we demonstrate the use of two different affinity tags for product capture and compare those to a tag-free self-cleaving intein capture technology. The intein purification method provided a product recovery of 86%, compared with 52% for conventionally tagged proteins, while resulting in a 30% increase in total units of activity of purified recombinant streptokinase compared with conventionally tagged proteins. These promising beneficial features combined with the intein technology makes feasible the development of dose-level production of therapeutic proteins at the point-of-care. |
Databáze: | OpenAIRE |
Externí odkaz: |